07:00 , May 26, 2014 |  BC Week In Review  |  Financial News

AssureRx completes venture financing

AssureRx Health Inc. , Mason, Ohio   Business: Pharmacogenetics   Date completed: 5/21/14   Type: Venture financing   Raised: $7 million   Investors: Sequoia Capital; Claremont Creek Ventures; Mayo Clinic ; Cincinnati Children's Hospital Medical...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Anacor management update

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif.   Business: Infectious, Dermatology, Autoimmune   Hired: Chairman Paul Berns as president and CEO, formerly president and CEO of Allos Therapeutics Inc. , which Spectrum Pharmaceuticals Inc. acquired;...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Belinostat: Final Phase II data

Final data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat led to an ORR of 26%, including a 10% complete...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Lycera management update

Lycera Corp. , Ann Arbor, Mich.   Business: Autoimmune, Transplant   Hired: Bruce Goldsmith as CBO, a newly created position, formerly SVP of corporate development at Allos Therapeutics Inc. , which Spectrum Pharmaceuticals Inc. acquired...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Belinostat: Additional Phase II data

Topotarget reported additional data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showing that once-daily IV belinostat led to an ORR that is "on par"...
02:28 , Mar 6, 2013 |  BC Extra  |  Clinical News

Topotarget gains on belinostat data

Topotarget A/S (CSE:TOPO) gained DKK0.61 (33%) to DKK2.46 on Tuesday after reporting that once-daily IV belinostat led to an objective response rate (ORR) that is "on par" with that of competing drugs Folotyn pralatrexate and...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

ImmunoGen management update

ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass.   Business: Cancer   Hired: Charles Morris as EVP and chief development officer, formerly EVP and CMO of Allos Therapeutics Inc. , which Spectrum Pharmaceuticals Inc. acquired  ...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Sutro management update

Sutro Biopharma Inc. , South San Francisco, Calif.   Business: Biomanufacturing   Hired: Jeremy Bender as CBO, formerly VP of corporate development at Allos Therapeutics Inc. , which Spectrum Pharmaceuticals Inc. acquired  ...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals cancer news

Spectrum said that the U.S. Patent and Trademark Office (PTO) extended by five years U.S. Patent No. 6,028,071 covering cancer drug Folotyn pralatrexate . The extension postpones the original July 16, 2017, expiration date to...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Allos, Spectrum Pharmaceuticals deal

Spectrum completed its acquisition of cancer company Allos for $1.82 per share in cash, or about $194.7 million (see BioCentury, April 9 & Aug. 27). Allos Therapeutics Inc. , Westminster, Colo.   Spectrum Pharmaceuticals Inc....